CI‐911: A placebo‐controlled study in patients with primary degenerative dementia

Maurice W. Dysken, Susan Anton‐Johnson, Linda Klein, Michael Kuskowski, Lawrence J. Schut, Steven H. Miles, Gabe J. Maletta, Richard De Jong

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Twenty patients with primary degenerative dementia participated in a 6‐week, doseranging, double‐blind, placebo‐controlled study of Cl‐911, a cognition activator that enhances performance in animal models of impaired cognition. Cl‐911 was well tolerated in these patients, but it did not result in significant improvement on objective measures of cognition, social functioning, or self‐care.

Original languageEnglish (US)
Pages (from-to)267-270
Number of pages4
JournalDrug Development Research
Volume12
Issue number3-4
DOIs
StatePublished - 1988

Keywords

  • Alzheimer's disease
  • clinical trial
  • nootropic

Fingerprint Dive into the research topics of 'CI‐911: A placebo‐controlled study in patients with primary degenerative dementia'. Together they form a unique fingerprint.

Cite this